SGLT2 inhibitors improve kidney and cardiac outcomes in patients with SLE and type 2 diabetes: JAMA
Taiwan: In a significant stride towards understanding and potentially managing nephritis in patients with systemic lupus erythematosus (SLE), a recent study has shed light on the promising role of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. This …